Fate seals new deal to develop natural killer cell therapies

28 June 2022

Japanese drugmaker Ono Pharmaceutical (TYO: 4528) and US biotech Fate Therapeutics (Nasdaq: FATE) have boosted their collaboration, adding the discovery of CAR-NK cell therapies to an existing agreement.

Since 2018 the firms have been working together to discover CAR-T cell therapies derived from induced pluripotent stem cells (iPSC), an approach which will continue to be used.

Fate’s iPSC platform is designed to deliver off-the-shelf cell products for delivery over multiple doses, boosting pharmacologic activity and including the potential for combination therapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK